Recs

2

An Unsurprising Pipeline Failure

By | More Articles
February 8, 2013 | Comments (1)

Eli Lilly (NYSE: LLY  ) announced yesterday that it would be ending its rheumatoid arthritis program for its drug tabalumab. In December, Lilly ended one of its three trials for this drug because it was showing no benefit, and it's now ended the other two trials for similar reasons. In the video, Brenton tells us about the drug's other potential application in the lupus space, and some other pipeline candidates it will be falling back on as it tries to gain share in the lucrative arthritis market.

The patent cliff cometh
Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 09, 2013, at 11:11 AM, HungryHunter12 wrote:

    I agree with the risk of banks dominating ETFs in developing markets. How does one find the consumer, health care and other attractive companies in those markets?

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 2244719, ~/Articles/ArticleHandler.aspx, 5/20/2013 9:03:45 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 15,335.28 -19.12 -0.12%
S&P 500 1,666.29 -1.18 -0.07%
NASD 3,496.43 -2.54 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/20/2013 4:00 PM
LLY $55.02 Down -0.88 -1.57%
Eli Lilly & Co. CAPS Rating: ****
PFE $28.70 Down -0.26 -0.90%
Pfizer CAPS Rating: ****
AMGN $102.18 Down -3.45 -3.27%
Amgen, Inc. CAPS Rating: ****

Advertisement